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Autosomal-dominant transthyretin (TTR)-related amyloidosis usually manifests in the second to over sixth decade with a length-dependent axonal neuropathy with prominent involvement of the small fibers and multi-organ systemic failure.

In Portugal and Sweden where Transthyretin Related Familial Amyloid Polyneuropathy (TTR-FAP) is endemic, disease prevalence ranges from 1 in 1.000 to 1 in 10.000 people. Beyond these endemic regions, the incidence of TTR-FAP is much lower.

More than 130 different mutations of TTR have been identified worldwide, but the first-described Val30Met mutation remains the most common with an early onset phenotype, which is typical in Portuguese population \[[@CR1]\]. The prevalence of different mutations varies according to ethnicity and geographic region. In Italy few regions (Sicily, Puglia, Lazio, Piedmont, Tuscan-Emilian Apennines) are endemic for specific mutations.

Early diagnosis is pivotal for effective therapeutic options, but it is hampered by the heterogeneity of the clinical spectrum in not-Portuguese populations, in which the divergences from the canonical phenotype are relevant \[[@CR2]\]. In the last years many groups described patients carrying *TTR* mutations and showing misleading clinical features \[[@CR3], [@CR4]\] or mimicking other neurological disorders as ALS \[[@CR5], [@CR6]\].

In 2011, Cappellari and colleagues reported atypical presentation of *TTR*-related familial amyloid polyneuropathy in Italian families. In their sample a relevant percentage of patients (76,4%; 13/17) received no diagnosis or a wrong diagnosis at onset, including Charcot-Marie-Tooth disease (CMT) in 2 patients.

The aim of our study was to search for *TTR* mutations in a large cohort of selected undiagnosed axonal sensory-motor neuropathy patients, classified as CMT2, to establish if CMT could occasionally mimic TTR-FAP. For this purpose, 98 consecutive patients, referred from all Italian Regions and affected with late onset axonal CMT (≥ 30 y), were enrolled at CMT Clinics of Ospedale Policlinico San Martino. Since we were looking for possible atypical *TTR* presentation, our selected cases had clinical features quite far from classic *TTR* phenotype. In particular, the mean age of onset was 46.4 years (SD: ±12,9 y; median 45 y) and the mean disease duration was 8.9 years (median: 4.5; range: some months -- 53 years). Main clinical features are summarized in Table [1](#Tab1){ref-type="table"}.Table 1Main clinical featuresTotal patients98Male51Female47Mean age55 yrMean onset46,4 ± 12,9 yrMedian onset45 yrMean disease duration8,9 ± 10,2 yrMedian disease duration4,5 yrPrevalent motor neuropathy13,20%Sensory motor neuropathy86,80%Hypoacusia4%Tremor1%*yr* years

All patients resulted negative for mutations in the most frequently mutated CMT2 genes (*MPZ, MNF2, GDAP1, GJB1, NEFL*). All patients underwent neurological and neurophysiological evaluation, had regular annual follow up at CMT Clinics and give informed consent to this genetic study.

No pathogenic *TTR* variants were found in this cohort.

Transthyretin-related amyloidosis is a severe multi-organ disease leading to death within 10 years after the first symptoms occur. Since several pharmacological treatments are now available \[[@CR7]--[@CR10]\], it is crucial to identify any potential case and to implement diagnostic strategies to reach an early diagnosis and plan a tailored therapy. In the early stages, a possible misdiagnosis with CIDP has been often reported and different authors recommend to consider *TTR*-related amyloidosis in cases presenting as immune-mediated neuropathies not responding to immunomodulant therapies \[[@CR3]\].

Coincident Diabetes Mellitus and Monoclonal Gammopathy of Undetermined Significance, both frequent particularly in elder population, could also mask a *TTR*-related amyloidosis \[[@CR11]\].

Charcot-Marie-Tooth disease is the most frequent inherited neuromuscular disorder and, in spite of a huge genetic heterogeneity, has peculiar clinical hallmarks as distal weakness and atrophy and pes cavus. The subgroup of patients presenting with a late onset axonal CMT2 could share some clinical features with *TTR* related amyloidosis, even if the course is often slowly instead of rapidly progressing.

Since Cappellari and colleagues identified a *TTR* mutation in two patients previously classified as CMT2 patients, we decided to screen a cohort of late onset CMT2 patients in which mutations in major CMT2-related genes have been excluded.

The study has some limitations. The number of CMT2 patients with a late onset, screened in this project, were referred from many Italian Regions in which *TTR* amyloidosis is not endemic and limited to 98 subjects, thus affecting the diagnostic yield.

However, although in a small sample, misdiagnosis of *TTR*-FAP in CMT2 patients seems not to be common.

In conclusion, our study shows that *TTR* testing not should be recommended in CMT2 patients but only when "red flags" TTR's features are present, such as a rapid progressive course, carpal tunnel syndrome particularly in males, cardiologic involvement or signs suggesting autonomic nervous system impairment.
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